Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2003; 89(02): 405-407
DOI: 10.1055/s-0037-1613458
DOI: 10.1055/s-0037-1613458
Letters to the Editor
Low molecular weight heparin treatment for malignant melanoma: a pilot clinical trial
Authors
Further Information
Publication History
Reiceved
16 August 2002
Accepted
20 August 2002
Publication Date:
07 December 2017 (online)
-
References
- 1 Balch CM, Buzaid AC, Soong S-J, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton Jr A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 9: 3635-48.
- 2 Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998; 80: 10-23.
- 3 Ornstein DL, Zacharski LR. Treatment of cancer with anticoagulants: rationale in the treatment of melanoma. Int J Hematol 2001; 73: 157-61.
- 4 Liu D, Shriver Z, Venkataraman G, El Shabrawi Y, Sasisekharan R. Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc Nat'l Acad Sci USA 2002; 99: 568-73.
- 5 Richmond RA, Thomas HG. Melanoma growth stimulating activity: isolation from human melanoma tumors and characterization of tissue distribution. J Cell Biochem 1988; 36: 185-98.
- 6 Zugmaier G, Favoni R, Jaeger R, Rosen N, Knabbe C. Polysulfated heparinoids selectively inactivate heparin-binding angiogenic factors. Ann NY Acad Sci 1999; 886: 243-8.
- 7 Mousa SA. Anticoagulants in thrombosis and cancer: the missing link. Semin Thromb Hemost 2002; 28: 45-52.
- 8 Bitan M, Mohsen M, Levi E, Wygoda MR, Miao HQ, Lider O, Svahn CM, Ekre HP, Ishai-Michaeli R, Bar-Shavit R. et al. Structural requirements for inhibition of melanoma lung colonization by heparinase inhibiting species of heparin. Isr J Med Sci 1995; 31: 106-18.
- 9 Zacharski LR, Wojtukiewicz MZ, Costantini V, Ornstein DL, Memoli VA.. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost 1992; 18: 104-16.
- 10 Zacharski LR, Memoli VA, Morain WD, Schlaeppi J-M, Rousseau SM. Cellular localization of enzymatically active thrombin in intact human tissues by hirudin binding. Thromb Haemost 1995; 73: 793-7.
- 11 Zacharski LR, Henderson WB. Vitamin K antagonists and cancer survival. Thromb Haemost 2002; 88: 173-4.
- 12 Micksche M. Production of polypeptide regulatory factors by human melanoma cells. In Vivo. 1994; 8: 859-65.
- 13 Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745-51.
- 14 Sciumbata T, Pirovano P, Pozzi P, Galimberti G, Leoni F, Marcucci F. Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival. Invasion Metastasis 1996; 16: 132-43.
- 15 Von TempelhoffG-F, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ, Heilmann L.. Effect of low molecular weight heparin. (Cetoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol. 2000; 16: 815-24.
- 16 Arbeit JM, Lowry SF, Line BR, Jones DC, Brennan MF.. Deep venous thromboembolism in patients undergoing inguinal lymph node dissection for melanoma. Ann Surg 1981; 194: 648-55.
- 17 Herlyn M, Satyamoorthy Melanoma.K.. In Cancer: Principles & Practice of Oncology. 6th edition. VT Jr. DeVita, Hellman S, SA Rosenberg. eds Philadelphia: Lippincott Williams & Wilkins; 2001: 2003-69.
- 18 Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Seipp CA, Einhorn JH, White DE, Steinberg SM. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with inter -leukin-2 and interferon alfa-2b. J Clin Oncol 1999; 17: 968-75.
- 19 Jorgensen LN, Iversen LH, Walenga JM, Prechel MM, Hoppensteadt DA, Rasmussen MS, Lausen I, Wille-Jorgensen P, Thorlacius-Ussing O. Anti-Xa levels in plasma predict late survival in patients after major surgery for malignancy receiving prophylaxis with low molecular weight heparins. Blood 2001; 98: 43a
- 20 Sylvester DM, Liu SY, Meadows GG. Augmentation of antimetastatic activity of interferon and tumor necrosis factor by heparin. Immunopharmacol Immunotoxicol 1990; 12: 161-80.